Emblation, the company behind the innovative Swift® microwave therapy system, announced today Tuesday 26 May, 2026 that its Swiftscope app is now available, allowing clinicians to visually track and show treatment progress. The Swiftscope™ app works in tandem with the SwiftPro® microwave device, which recently earned FDA 510(k) clearance for the treatment of common and plantar warts.
“We are pleased to announce the launch of the Swiftscope app, which provides clinicians the ability to capture and compare treatments and visually show their patients to help educate them about their diagnosis and treatment journey,” said Ian Stevens, chief executive officer of Emblation. “The addition of the Swiftscope app is part of our ongoing commitment to support clinicians and patients globally with tools that strengthen confidence, trust and clinical outcomes.”
Unlike traditional methods that can cause damage and discomfort, the company’s microwave heat therapy activates the immune system to clear skin conditions naturally, delivering better outcomes with less pain than traditional methods, and is safe and more tolerable for patients.
The Swiftscope app allows clinicians to capture consistent images of the condition, compare progress side-by-side, show patients changes at each appointment, and confidently guide patients through treatment. The app integrates with leading smartphone and iPad dermatoscopes, enabling clinicians to capture high-quality clinical and dermoscopic images with seamless documentation.
“Treating common and plantar warts can be a challenging process for patients, often requiring weeks or months of consistent treatment,” said Tracey Vlahovic, DPM, Bay Area Foot Care. With the Swiftscope app, I can show patients exactly how their treatment is working in real-time. Giving patients that visual understanding of progress from the very first appointment keeps them motivated, and it’s incredibly rewarding to hear them say, ‘I can actually see it working.'”
SwiftPro and the Swiftscope app are available in many global markets, including the U.S., U.K., and Canada. For more information visit swiftbyemblation.com.
About Emblation
Based in Stirling, Scotland with U.S. headquarters in Lincoln, R.I., Emblation launched Swift® in 2016. Since then, over 650,000 treatments have been conducted globally with over 85% of patients experiencing complete resolution and a low recurrence rate compared to traditional methods. The company recently received FDA 510(k) clearance for expanded indications of its Swift and SwiftPro® Systems for the treatment of common and plantar warts.
Media Contact:
Emblation
844-793-8776
